Standout Papers

Exon skipping and dystrophin restoration in patients with Duchenne musc... 2006 2026 2012 2019 645
  1. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study (2011)
    Sebahattin Çirak, Virginia Arechavala‐Gomeza et al. The Lancet
  2. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? (2019)
    Loren L. Flynn, Ianthe Pitout et al. Frontiers in Neuroscience
  3. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology (2006)
    J. Alter, Fang Lou et al. Nature Medicine

Immediate Impact

13 by Nobel laureates 24 from Science/Nature 66 standout
Sub-graph 1 of 18

Citing Papers

Future therapies for cystic fibrosis
2023 Standout
Cystic Fibrosis
2023 Standout
3 intermediate papers

Works of Steve D. Wilton being referenced

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation
2021
WS1.5 Restoration of the CFTR function by antisense oligonucleotide splicing modulation
2014
and 2 more

Author Peers

Author Last Decade Papers Cites
Steve D. Wilton 7217 1756 1872 218 9.2k
Silvère M. van der Maarel 9788 1483 2154 237 12.1k
Keiya Ozawa 6240 2739 2441 335 11.9k
George Dickson 6461 1953 848 171 7.6k
Vincent Mouly 6941 769 1408 202 8.7k
Lawrence W. Stanton 6829 1066 708 123 10.3k
G. Diane Shelton 3156 906 669 279 6.3k
Jocelyn Laporte 6761 990 1025 255 9.3k
Joseph D. Rosenblatt 3621 929 1583 222 12.5k
Paolo Bonaldo 6457 1191 967 163 12.0k
Stephen D. Hauschka 9619 2382 819 121 11.9k

All Works

Loading papers...

Rankless by CCL
2026